Piramal Pharma Ltd

(PPLPHARMA)

Piramal Pharma Stock Shows Potential for Recovery - 22 Nov, 2024

Piramal Pharma Ltd has doubled investors' wealth over the past year. After recent profit-taking, the stock is showing support above the 50-EMA, indicating potential for a bullish comeback. Short-term traders are advised to consider buying with targets set between Rs 280-286.

Piramal Pharma Confident Amid US Market Uncertainty - 21 Nov, 2024

Piramal Pharma remains optimistic about navigating US market volatility despite potential uncertainties from Trump's return. The company plans significant investments in existing facilities and aims to reduce debt while expanding its consumer healthcare sales.

Piramal Pharma Reports Strong Q2 Performance - 13 Nov, 2024

Piramal Pharma has shown strong performance with a 15% revenue growth and 11% EBITDA growth year-on-year in the September quarter. The stock has gained 14% over the last two months, reflecting positive market sentiment.

Piramal Pharma Shares Decline Despite Long-Term Growth - 12 Nov, 2024

Piramal Pharma shares fell over 4%, trading at ₹257.95, after dropping as much as 5% earlier. Despite this decline, the stock has increased by 124.9% over the past year.

Piramal Pharma Hits 52-Week High with 9% Surge - 06 Nov, 2024

Piramal Pharma shares surged over 9%, reaching a 52-week high of Rs 299.40 amid strong trading volumes, reflecting heightened investor interest and market optimism.

Piramal Pharma Stock Soars Post Q2 Results - 31 Oct, 2024

Piramal Pharma's stock surged 25% in six days, reaching a new high of Rs 274.80 after strong Q2FY25 results, driven by growth in the CDMO segment and an $80 million expansion plan.

Piramal Pharma Hits 52-Week High on Strong Performance - 29 Oct, 2024

Piramal Pharma's stock surged 7.09% to a 52-week high of ₹263.90, driven by robust CDMO segment growth and a 17.28% YoY revenue increase to ₹2,242 crore in Q2 FY25. The company has invested $80 million in capacity expansion, reflecting positive market momentum.

Piramal Pharma Breaks Out, Plans Major Capex - 28 Oct, 2024

Piramal Pharma has broken out from a 6-week consolidation, with experts recommending a buy targeting Rs 280. The company also plans an $85 million capex for expansion and maintenance.

Piramal Pharma Plans Significant Capex Investment - 27 Oct, 2024

Piramal Pharma announced an investment of USD 85 million for capacity expansion and maintenance, targeting over USD 2 billion in revenue by FY30. The company reported a four-fold increase in net profit for Q2, reaching Rs 23 crore, with revenues of Rs 2,242 crore, up from Rs 1,911 crore year-on-year.

Piramal Pharma Reports Strong Earnings Amid Share Dip - 25 Oct, 2024

Piramal Pharma reported a 17% revenue increase and a 350% profit surge in Q2 FY25. Despite strong results, shares dipped, prompting Jefferies to maintain a buy rating with a target of Rs 260.

Piramal Pharma Reports Strong Q2 FY25 Financials - 24 Oct, 2024

Piramal Pharma's Q2 FY25 results show a 350% increase in net profit to ₹23 crore and a 17% rise in revenue to ₹2,242 crore. The company plans to expand its capabilities to meet rising demand.